Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, et al. Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol 2022 Sep 29. pii: S1470-2045(22)00555.
PMID: 36183733